Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Covid-Related Sales Boost BioNTech, Moderna and Gilead
03:21pm, Tuesday, 27'th Sep 2022
Covid-related product sales helped make BioNTech SE ( BNTX , Financial), Moderna Inc. ( MRNA , Financial), Gilead Sciences Inc. ( GILD , Financial) and Regeneron Pharmaceuticals Inc. ( REGN , Financia
Drugmaker stocks lead sector with healthy dividends
03:50pm, Friday, 23'rd Sep 2022
CNBC's Bertha Coombs reports on health care stocks.
Health care stocks with dividend yields to weather through market turmoil
09:19am, Friday, 23'rd Sep 2022
The healthcare sector is an investor favorite in a defensive market. CNBC's Bertha Coombs joins 'Squawk Box' to break down some players with the best dividend yields.
A Dive Into Gilead Sciences' New HIV Medication
10:34am, Thursday, 22'nd Sep 2022
We look at an overview of Gilead's HIV medication. Gilead currently pays a 4.52% dividend.
WHO Recommends Gilead's (GILD) Veklury for Severe COVID-19
04:33pm, Friday, 16'th Sep 2022
Gilead's (GILD) Veklury is now recommended by the WHO for use in both non-severe COVID-19 patients at the highest risk of hospitalization and those with severe COVID-19.
A flurry of regulatory announcements relating to COVID treatments, vaccines and boosters dominated headlines on the pandemic Friday, with Europe now considering giving vaccines full marketing authoriz
EU regulator recommends extending Gilead's COVID treatment Veklury for use in pediatric patients
06:56am, Friday, 16'th Sep 2022
Gilead Sciences Inc. GILD, -0.28% said Friday the European regulator has adopted a positive opinion on extending the use of its COVID treatment Veklury for pediatric patients. The European Commission
Gilead COVID-19 drug gets expanded WHO recommendation
06:48pm, Thursday, 15'th Sep 2022
Gilead Sciences Inc. GILD, -0.28% said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker's COVID-19 treatment Veklury. In a statement, th
Gilead Sciences, Inc. (GILD) Presents at Baird 2022 Global Healthcare Conference (Transcript)
12:55pm, Wednesday, 14'th Sep 2022
Gilead Sciences, Inc. (NASDAQ:GILD ) Baird 2022 Global Healthcare Conference September 14, 2022 9:30 AM ET Company Participants Johanna Mercier - Chief Commercial Officer Conference Call Participants
My Biggest Worry About Gilead Sciences
05:52am, Wednesday, 14'th Sep 2022
The biotech company could become a victim of its own success -- again.
Gilead (GILD) Up on Settling HIV Drug Suit With Generic Players
06:48pm, Tuesday, 13'th Sep 2022
Gilead (GILD) enters settlement agreements with a few generic manufacturers to resolve the litigation and patent challenges associated with HIV treatments, such as Descovy, Vemlidy and Odefsey.
3 Unstoppable Dividend Stocks to Buy in September
05:25am, Tuesday, 13'th Sep 2022
These stocks offer more than just dividends.
Why Is Gilead Sciences (GILD) Stock Up Today?
03:25pm, Monday, 12'th Sep 2022
Gilead Sciences (NASDAQ: GILD ) is up about 5% on Monday, with GILD stock jumping on news the company is finally settling a patent lawsuit. The settlement involves Gilead's generic HIV drugs, Descovy
Gilead's stock jumps 5% after setting patent case related to HIV therapies
09:08am, Monday, 12'th Sep 2022
Shares of Gilead Sciences Inc. GILD, +0.28% were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its
Gilead (GILD) Breast Cancer Drug Trodelvy Improves Survival
01:32pm, Thursday, 08'th Sep 2022
Gilead (GILD) breast cancer drug Trodelvy demonstrates a statistically significant and clinically meaningful improvement of 3.2 months in overall survival compared to chemotherapy.
